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Background. Three members of the small integrin-binding
ligand N-linked glycoprotein (SIBLING) family of proteins
have recently been shown to bind and activate specific proma-
trix metalloproteinases (MMPs) and to overcome the inhibition
of tissue inhibitors of MMPs (TIMPs). Although usually asso-
ciated with mineralized tissues, we have shown that the SIB-
LINGs and their MMP partners, when known, are coexpressed
in salivary gland ductal cells. The present study examined the
expression patterns of both the SIBLINGs and their MMP part-
ners in adult kidney.
Methods. The expression patterns of all five SIBLINGs
known to date, and their MMP partners were determined in
monkey kidney using immunohistochemistry and in situ hy-
bridization techniques.
Results. Bone sialoprotein (BSP) and its partner, MMP-2,
were coexpressed in both the proximal and distal tubules. Os-
teopontin, as previously shown, was expressed in the distal
tubules while its partner MMP-3 was expressed in both the prox-
imal tubule and distal tubles. Dentin matrix protein-1 (DMP1)
and MMP-9 were coexpressed throughout the nephron, includ-
ing both parietal cells of Bowman’s capsule and the thin limb of
the loop of Henle. Dentin sialophosphoprotein (DSPP) and ma-
trix extracellular phosphoglycoprotein (MEPE) were expressed
in the proximal tubule and distal tubule, and proximal tubule,
respectively.
Conclusion. In contrast to salivary gland in which all SIB-
LINGs and their MMP partners were coexpressed throughout
the length of the ducts, these proteins were differentially ex-
pressed within the normal adult nephron. We hypothesize that
the cells use the SIBLING/MMP pairs in the normal turnover
of cell surface proteins and/or pericellular matrix proteins such
as those in basement membranes.
The Small Integrin-Binding LIgand N-linked Glyco-
proteins (SIBLINGs) are a family of five secreted pro-
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teins characterized by common exon-intron features, the
presence of the integrin-binding tripeptide, Arg-Gly-
Asp (RGD), and several conserved phosphorylation and
N-glycosylation sites [1]. The SIBLINGs include os-
teopontin (OPN; also known as uropontin in the kid-
ney field [2, 3]); bone sialoprotein (BSP); dentin matrix
protein-1 (DMP1); dentin sialophosphoprotein (DSPP);
and matrix extracellular phosphoglycoprotein (MEPE).
The SIBLING genes are clustered together on human
chromosome 4 and mouse chromosome 5 [4]. The four
acidic members of the family (BSP, DMP1, DSPP, and
OPN) were discovered years ago associated with the ma-
trices of bones and teeth by many laboratories [5] while
the basic protein, MEPE, was discovered more recently
in association with tumors that cause phosphate wasting
[6].
With the exception of osteopontin, expression of the
SIBLINGs in normal adults was generally thought to be
limited to mineralized tissues (i.e., the bones and teeth).
The presence of OPN in normal nonmineralizing tis-
sues, including the kidney [7, 8] lactating breast [9], and
immune cells [10], has been well documented. Its up-
regulation in renal tubules, particularly the distal tubules,
has been demonstrated in renal patients and several mod-
els of renal injury suggesting that it is an important
mediator of tubulointerstitial injury possibly by facilitat-
ing tissue remodeling and repair [11–15]. With respect
to renal calcium stone matrix physiology, the role of os-
teopontin is less clear, with some reports indicating that it
inhibits [8, 16–20], and others suggesting that it promotes,
renal stone formation [20, 21].
Matrix metalloproteinases (MMPs) are a family of
over 20 zinc-dependent enzymes that degrade a wide
variety of proteins, including those in the extracellular
matrix (ECM) [22]. They are secreted as proenzymes
(pro-MMPs) that classically are transformed into active
forms upon cleavage of a propeptide domain [23]. Re-
cently, however, we have shown in vitro that at least three
SIBLINGs can bind and activate specific pro-MMPs ap-
parently without removing the propeptides [24]. Further-
more, the same SIBLING/MMP pairs are substantially
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more resistant to inhibition by tissue inhibitors of MMPs
(TIMPs) [24]. The activities of MMPs have been impli-
cated in a variety of normal and pathologic cellular pro-
cesses, including organ involution during development,
wound healing, and tumor cell invasion [25]. Normal ep-
ithelial cell expression of MMPs include placental tro-
phoblasts [26–30], ameloblasts [31, 32], pancreatic ducts
[33], breast ductal epithelium [34–36], and salivary gland
ducts [37]. They have also been reported to be involved in
renal development [38]. Reports of the precise localiza-
tions of MMP-2, MMP-3, and MMP-9 in primate normal
adult kidney, however, are surprisingly sparse, perhaps
due to the lack of specificity of many of the antibodies pre-
viously used for primate nephrons. There are reports of in
vitro studies showing the presence of MMP-2 and MMP-
9 in cell lines of the different segments of the nephron,
including the glomerulus [39, 40]. In several papers in
which various naturally occurring or induced kidney dis-
eases have been studied, there are statements of baseline
activities of these three MMPs but little evidence of spe-
cific sites of expression along the nephron [33, 41–43]. The
studies of Piedagnel et al [39] directly probed the in vivo
presence of two MMPs in normal rat kidney. The authors
indicated that MMP-2 and -9 proteins were present in the
collecting ducts of rat nephron [39].
Investigation of the localization of the SIBLINGs and
their partner MMPs in normal kidney was initiated af-
ter our discovery that the SIBLINGs and their MMP
partners were coexpressed in the epithelial cells of the
ducts of normal salivary glands [37]. The two SIBLINGs
without known MMP partners, DSPP and MEPE, were
also expressed in the relatively simple ductal system of
the salivary glands [37] even though they are usually
thought to be limited to bones and teeth. The coexpres-
sion of all SIBLINGs and their MMP partners through-
out the entire length of the salivary gland ducts, however,
make it difficult to differentiate among the different roles
that the individual SIBLING-MMP pairs may play in the
normal physiology of mature, metabolically active ducts.
As presented here, the nephron, with its more complex
physiology, exhibits differential expression of both the
SIBLINGs and their MMP partners, thereby suggesting
that the proteins may have distinct but related functions.
We propose that these functions may include the enzy-
matic digestion of cell surface and/or pericellular ma-
trix proteins damaged by oxidative byproducts invariably
produced by such active cells.
METHODS
Tissue collection
Fresh surgical waste kidneys of monkey (M. fasci-
cularis) were obtained from the Tissue Distribution
Program of the National Primate Research Center (Uni-
versity of Washington, Seattle, WA, USA). Mouse kid-
neys were obtained as surgical wastes from normal mice
previously culled from a breeding pool. Sagittal slices of
the tissue specimens were fixed in 10% neutral-buffered
formalin for 24 to 48 hours and routinely processed
for paraffin embedding. Normal human kidney and pla-
centa (for MMP antibody positive controls) paraffin
blocks without patient identifiers were obtained from the
Mid-Atlantic Division of the Cooperative Human Tis-
sue Network (Charlottesville, VA, USA) under an NIH-
approved (exempt) protocol. Three micron sections were
cut and processed under strict RNAse-free conditions.
Sections of rat kidney (69687-3) were purchased from
Novagen (Madison, WI, USA).
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Human kidney total RNA (64097-1) was purchased
from BD Biosciences (Palo Alto, CA, USA). One micro-
gram of total RNA was reverse transcribed and amplified
by PCR for each gene product using the Superscript III
One-Step RT-PCR System (Invitrogen, Carlsbad, CA,
USA) and the intron-spanning oligonucleotide pairs de-
scribed below. The cDNAs were reverse transcribed for
15 minutes at 60◦C, denatured at 94◦C for 2 minutes, and
then amplified for 45 cycles of 30 seconds each (denatu-
ration 94◦C, annealing 60◦C, and extension 68◦C) with a
final extension at 68◦C for 7 minutes. Products were elec-
trophoresed on a 6% polyacrylamide gel in Tris-borate-
ethylenediaminetetraacetic acid (EDTA) (TBE) buffer,
stained with ethidium bromide, and photographed.
Standard are X174 DNA digested with HaeIII (New
England Biolabs, Beverly, MA, USA). The oligonu-
cleotides used were as follows: BSP forward (exon 6), GT
TAGCTGCAATCCAGCTTCC; BSP reverse (exon 7),
GAGAGGTTGTTGTCTTCGAGG; DMP1 forward
(exon 5), GGCAGTAAAGTTAGCTCAGAGG; DMP1
reverse (exon 6), CTCTCTTCACTGGCTTGTATG;
DSPP forward (exon 4), GAATCAGAGACACATGCT-
GTTGG; DSPP reverse (exon 5), GGGATCATCTCC
TTGCATGG; osteopontin (OPN) forward (exon 5),
GTTTCGCAGACCTGACATCC; OPN reverse (exon
6), CATGGCTGTGGAATTCACGG; MEPE forward
(exon 3), CTGTGTGGAAGAGCAGAGG; MEPE
reverse (exon 4), GCTGATAGCATCATCTCCATCC;
MMP-2 forward (exon 12), CCAAGCTCATCGCAG
ATGCC; MMP-2 reverse (exon 13), TACAGTCAGC
ATCTATTCTTGGG; MMP-3, forward (exon 9), GAG
AAGAGAAATTCCATGGAGC; MMP-9 forward
(exon 12), GACGTGAAGGCGCAGATGG; and
MMP-9 reverse (exon 13), CCTTTCCTCCAGAACA-
GAATACC.
Immunohistochemistry
Mouse monoclonal and rabbit polyclonal antisera to
the SIBLINGs have been previously described to work
in paraffin sections of monkey tissues [37] and are
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Table 1. Antisera and riboprobes
Antisera
Antigen ID Description Dilution Typea
Human BSPa LFMb-25 Carboxy-terminal region 10 lg/mL Mouse IgG1
Human DSPPa LFMb-21 DPP domain CSRGDASYNSDESKDNG 2.5 lg/mL Mouse IgG2b
Human OPNa LFMb-14 Just C-terminal to RGD 2.5-10 lg/mL Mouse IgG2b
Human MEPE LFMb-33 Within last exon 3.3 lg/mL Mouse IgG1
Human MEPEa LF-155 Within last exon 1:200 dilution Rabbit polyclonal
Human DMP1 LFMb-31 Peptides (Jain et al 2002) 20 lg/mL Mouse IgG1
Human BSPa LF-84 (Mintz et al 1993) 1:200 dilution Rabbit antibodyb
Mouse OPN LF-175 Bacterial recombinant 1:200 dilution Rabbit polyclonal
Human MMP-2 AB807 (Chemicon, Temecula, CA) 1:100 dilution Rabbit polyclonalb
Human MMP-3 MAB3306 (Chemicon, Temecula, CA) 10ug/mL Mouse IgG1
Human MMP-9 RB-1539 (Lab Vision, Fremont, CA) 1:200 dilution Rabbit polyclonal
Riboprobes
Target ID Description Insert Plasmid/Reference
Human:
BSP B6-5g Full-length coding cDNA 1.2 kbp pBluescript (Fisher et al 1990)
DMP1 hDMP1 - E5 - 3 Coding in last exon by PCR 1.4 kbp pBluescript (Ogbureke, Fisher 2004)
DSPP hDSPP-1 DSP portion of DSPP exon 4 by PCR 0.7 kbp pBluescript (Ogbureke, Fisher 2004)
DSPP hDPP510 (Nonrepeat) DPP of exon 4 by PCR 215 pb pBluescript (Ogbureke, Fisher 2004)
MEPE hMEPEx45 Full-length cDNA lacking exons 4 and 5 1.6 kbp pBluescript (Ogbureke, Fisher 2004)
OPN OP10 Full-length cDNA lacking exon 4 1.5 kbp pBluescript (Young et al 1990)
MMP-2 hMMP2 Portion last exon by PCR ∼320 bp pBluescript (Ogbureke, Fisher 2004)
MMP-3 hMMP3 portion last exon by PCR ∼340 bp pBluescript (Ogbureke, Fisher 2004)
MMP-9 hMMP9 portion last exon by PCR ∼320 bp pBluescript (Ogbureke, Fisher 2004)
Abbreviations are: BSP, bone sialprotein; DSPP, dentin sialophosphoprotein; OPN, osteopontin; MEPE, matrix extracellular phosphoglycoprotein; DMP, dentin
matrix protein; MMP, matrix metalloproteinase; PCR, polymerase chain reaction.
aCross to mouse on paraffin sections.
bAffinity purified.
summarized in Table 1. Although only monoclonal an-
tibody results are shown for SIBLINGs, each result was
verified using the appropriate rabbit polyclonal anti-
serum. Also, a series of commercial mouse monoclonal
and rabbit polyclonal antibodies suggested to work in
paraffin sections of human tissues were screened for their
ability to detect MMP-2, MMP-3, or MMP-9 in sections of
human placenta. Two commercial monoclonals (one each
for MMP-2 and MMP-3) worked under our conditions as
did two polyclonals (for MMP-2 and MMP-9) (Table 1).
The two antibodies to MMP-2 (polyclonal, AB807, and
monoclonal, MAB 13431) and the monoclonal antibody
to MMP-3 (MAB 3306) were purchased from Chemi-
con (Temecula, CA, USA). Antibody to human Tamm-
Horsfall protein (THP) was purchased from Cedarlane
(Hornby, Ontario, Canada). Affinity-purified rabbit poly-
clonal antisera to mouse aquaporins 1, 3, and 4 with
known cross-reactivity to human and monkey kidneys
[44] (generous gifts from Dr. Mark Knepper, NIDDK,
NIH, Bethesda, MD, USA) were used to verify the iden-
tity of the proximal tubule (aquaporin 1), thin limb of
Henle (aquaporin 1), and collecting duct (aquaporins 3
and 4) when morphology alone was insufficient.
Immunostaining was performed at room temperature
using the Zymed ST5050 automated system (Zymed Lab
Inc., San Francisco, CA, USA). In brief, paraffin sections
of monkey kidney were manually dewaxed in xylene and
rehydrated through graded ethanol (100%, 95%, and
70%) and water. Endogenous peroxidase activity was
then inhibited by treating the sections with 3% hydro-
gen peroxide in methanol for 20 minutes at room tem-
perature. Sections were thereafter washed three times
in phosphate-buffered saline (PBS) for at least 5 min-
utes each and covered with PBS + Tween-20 (PBS-T)
before loading the slides on to the preprogrammed
ST5050 automated immunohistochemistry machine. The
ST5050 was programmed to incubate each slide for one
hour with corresponding SIBLING/MMP antibody di-
luted in 10% normal goat serum in PBS (see Table 1 for
specific dilutions). The sections thereafter went through
a 4 × 1-minute wash cycle with PBS-T before incuba-
tion with SuperPicTure Polymer horseradish peroxidase
(HRP)-conjugated broad-spectrum secondary antibody
(87-8963) (Zymed Lab. Inc.) for 10 minutes. The sec-
tions were passed through another wash cycle and then
developed with AEC Single Solution chromogen (00-
1122) (Zymed Lab. Inc.) for 2 minutes. All steps were
done at room temperature. Sections were then lightly
counterstained manually with Mayer’s hematoxylin for
10 to 20 seconds before applying an overlay of Clear-
mount (Zymed Lab. Inc.) glaze over the sections. Af-
ter air-drying, slides were coverslipped with Histomount
(Zymed Lab. Inc.). Negative controls included the substi-
tution of primary antibody with nonimmune rabbit serum
or mouse IgG control (08–6599) (Zymed Lab. Inc.). Pho-
tographic images of representative results were captured
158 Ogbureke and Fisher: Renal expression of SIBLINGs and MMPs
using the Axioplan2 Universal microscope equipped with
an Axiovision digital camera and the company’s Axiovi-
sion program (Carl Zeiss GmbH, Jena, Germany).
In situ hybridization
A summary of the antisense and sense riboprobes for
the SIBLINGs and MMPs is shown in Table 1. Human
SIBLING and MMP probes that cross-hybridized with
corresponding monkey mRNAs were used for the mon-
key kidney sections. We have recently described in de-
tail the methods used for the synthesis of the probes
for nonradioactive detection of mRNA transcripts [37].
In brief, digoxigenin (DIG) labeling of the probes was
carried out using the DIG RNA Labeling Mix (Roche
Diagnostic GmbH, Mannheim, Germany), the appropri-
ately linearized cDNA plasmid, and the corresponding
RNA polymerases. For in situ detection of transcripts
with the 5-bromo-4-chloro-3-indoyl phosphate/nitro blue
(BCIP/NBT) final color reagent, the InnoGenexTM Uni-
versal ISH Kit SH-3018-01 (InnoGenex, San Ramon, CA,
USA) was used following the manufacturer’s instructions.
Temperature control during the in situ hybridization was
carried out with the aid of the OmniSlide Thermal Cy-
cler (Thermo Electron Corp., Milford, MA, USA). All
aqueous solutions were constituted in RNAse-free wa-
ter. The amount of sense probe used as negative control
was always greater than that used for the antisense (as de-
termined by comparing the relative strength of the DIG
labeling using serial dilutions and dot blots on charged
nylon membranes with subsequent detection using alka-
line phosphatase–conjugated anti-DIG antibodies). Fast
Red was used as the nuclear counterstain. As with the
immunohistochemistry results, representative images of
posthybridization sections were captured using the Ax-
ioplan2 Universal Microscope system.
Segment notations and scoring system for SIBLING/
MMP expression
There are many accepted notations of the different seg-
ments of the primate nephron and we have chosen the
nomenclature illustrated in Figure 1A. A threshold in-
tensity of the AEC red/brown-colored staining was based
on negative control sections treated with either preim-
mune rabbit serum for polyclonal antibodies or inactive
mouse IgG antibody as indices for negative staining of
the various kidney structures (example, Fig. 2L). Positive
staining for either the SIBLINGs or MMPs was based on
consistent staining of any structure type visibly exceeding
the threshold observed for the negative controls. Tubu-
lar profiles were scored as positive for SIBLING/MMP,
only when 50% or more of the cells of a tubular
cross-section in the cortex or medulla exhibited staining
intensity exceeding the baseline established by the neg-
ative control staining. Tubules not visualized in their en-
tirety were not assessed. Concurrent with assessment of
the intensity of staining, homogeneity of staining was as-
sessed before assigning numerical score. Depending on
the degree to which the intensity of staining exceeded
the baseline (control), positive staining was semiquanti-
tatively recorded as +, ++, or +++ in ascending order of
intensity. Segments exhibiting focal staining were scored
as +/−.
RESULTS
RT-PCR demonstrates presence of SIBLINGs
and MMPS
The presence of the five SIBLINGs as well as MMP-
2, MMP-3, and MMP-9 in kidney was first determined
by RT-PCR of total RNA obtained from normal adult
human kidney. The oligonucleotide pairs used in this ex-
periment each spanned an intron to distinguish cDNA
copied from mRNA by the reverse transcriptase from a
larger band that would have been the result of contami-
nating genomic DNA. In each case, a band corresponding
to the mRNA for each of the SIBLINGs and the three
MMPs was observed (Fig. 1B).
Immunohistochemical and in situ localization
of SIBLING/MMP
A summary of the semiquantitative distribution of the
SIBLINGs and their partner MMPs in the various seg-
ments of the nephron, as determined by immunohis-
tochemistry is presented in Table 2. While the entire
kidney was subject to microscopic observation for both
protein and mRNA content, for brevity only the three
major morphologic regions (cortical labyrinth, medullary
rays, and the medullary pyramid) that present all of the
segments of the various nephrons are illustrated in the
histologic results. Red/brown coloration of tissue ele-
ments represents positive immunohistochemistry after
staining with AEC chromogen, while bluish coloration
reflects nuclear counterstain with hematoxylin. For the in
situ hybridization results, the purplish/blue staining rep-
resents positive results for the specific mRNA after stain-
ing with BCIP/NBT chromogen, while red coloration
reflects the Nuclear Fast Red counterstain.
Osteopontin/MMP3
Osteopontin was restricted to the distal convoluted
tubules and distal straight tubules in the cortex (Fig. 2A)
and medullary regions (Figs. 2B and 3C) of the nephron as
summarized as the red color in the schematic (Fig. 2D and
Table 2). The identity of osteopontin-positive tubules was
verified by showing localization of the distal tubules pro-
tein, THP, within the same tubules in serial or near-serial
sections (Fig. 2E). Except for the most distal portion of
the distal convoluted tubule abutting the collecting duct









































Fig. 1. (A) Schematic of the functional seg-
ments of the nephron. Abbreviations are:
BC, Bowman’s capsule; GL, glomerulus; PCT,
proximal convoluted tubule; PST, proximal
straight tubule; TnLH, thin limb of the loop of
Henle; DST, distal straight tubule; DCT, dis-
tal convoluted tubule; CD, collecting duct. (B)
The presence of the small integrin-binding lig-
and N-linked glycoproteins (SIBLINGs) and
matrix metalloproteinase (MMP)-2, MMP-
3, and MMP-9 in normal kidney tissue de-
termined by reverse transcription-polymerase
chain reaction (RT-PCR) of total RNA. Ab-
breviations are: BSP, bone sialprotein; DSPP,
dentin sialophosphoprotein; OPN, osteopon-
tin; MEPE, matrix extracellular phosphogly-
coprotein; DMP1, dentin matrix protein.
(in which THP shows only weak staining), OPN and THP
were both highly expressed along the full length of the
distal tubules (Fig. 2A and E, arrows). As was the case in
the salivary ducts, the OPN protein was observed partic-
ularly concentrated along the basal portions of the cells
irrespective of the antibody that was used and whether
the kidney was that of adult monkey (Fig. 2A, arrow), rat
(Fig. 2I to K) human (data not shown), or mouse (data
not shown). The mRNA for OPN was limited to the same
distal tubule segments as for the protein (Fig. 2F and G).
Typical nonreactive IgG antibody negative control (Fig.
2L) and osteopontin mRNA riboprobe sense strand (Fig.
2H) are shown.
MMP-3, previously shown to be bound and activated
by OPN in vitro, also localized along the distal tubules
(distal straight tubule and distal convoluted tubule) at
both the protein (Fig. 2M to O) and mRNA (Fig. 2Q to
S) levels. Interestingly, MMP-3 was also present in the
proximal tubules (proximal convoluted tubule and prox-
imal straight tubule) (Fig. 2M and N, arrows), segments
that do not express OPN. Figure 2P (red) schematic sum-
marizes this distribution of MMP-3 along the nephron.
Figure 2T is a typical representation of the sense strand
negative control for MMP-3 mRNA. The wider scope
of MMP-3 distribution than that of its SIBLING partner,
OPN, illustrates the point that the partner MMP is always
found where a SIBLING is expressed, but the MMP can
also be found in locations without its SIBLING partner.
BSP/MMP2
BSP and its partner, MMP-2, were more widely dis-
tributed than OPN/MMP-3 in the adult monkey nephron
(Fig. 3). The staining pattern of BSP and MMP-2 by
both antisera and in situ hybridization indicated a weak
but clear presence in the proximal convoluted tubule,
proximal straight tubule, distal straight tubule, and distal
convoluted tubule in both the cortex and medulla (Fig.
3A to P). The collecting duct demonstrated focal stain-
ing for BSP protein (Fig. 3C, asterisk), but local synthe-
sis could not be confirmed by in situ localization of its
respective mRNA (Fig. 3G, asterisk). The immunohis-
tochemistry distributions of BSP and MMP-2 are sum-
marized as red areas in Figure 3D and L schematics,
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Table 2. Small integrin-binding ligand N-linked glycoprotein (SIBLING) and matrix metalloproteinase (MMP) expression in monkey nephron
Proximal convoluted Proximal straight Thin limb of Distal straight Distal convoluted Collecting
Glomerulus tubule tubule Henle tubule tubule duct
BSP − + + + + − + + + + +/−
MMP-2 − + + + + − + + + + +/−
OPN − − − − + + + + + −
MMP-3 − + + − + + + + −
DMP1 + (PC) + + + + + + + −
MMP-9 + (PC) + + + + + + + −
DSPP − ++ + − + + +/−
MEPE − + + + − − − −
THPa − − − − + +++ −
Abbreviations are: BSP, bone sialprotein; DSPP, dentin sialophosphoprotein; OPN, osteopontin; MEPE, matrix extracellular phosphoglycoprotein; DMP, dentin
matrix protein; MMP, matrix metalloproteinase; PC, parietal cells; THP, Tamm-Horsefall protein; +, some expression; −, no expression; + +, increased expression; +
+ +, mid-spread, strong expression; +/−, focal and/or low level expression by immunohistochemistry not verifiable at mRNA level.
aPositive control for osteopontin localization.
respectively. Figure 3H and P represent sense strand con-
trol results for BSP and MMP-2 mRNA, respectively.
The presence of BSP and MMP-2 proteins but not their
mRNA in the collecting duct suggests that these secreted
proteins may be released at least in part into the lu-
men from more upstream nephron segments later to
be bound to the lumen surfaces of the collecting duct.
The thin limb of Henle and glomeruli were all negative for
BSP and MMP-2. Unlike OPN, BSP and MMP-2 protein
distribution encompassed the entire basoluminal width of
the cell, presumably due to the localization of these se-
creted protein within the rough endoplasmic reticulum,
Golgi, and various secretory vesicles.
DMP1/MMP-9
Immunohistochemistry staining (Fig. 4A to C) and in
situ hybridization (Fig. 4E to G) of DMP1 show that
this protein was expressed in virtually all segments of
the nephron as summarized in Figure 4D schematic. Im-
munohistochemistry staining in the distal tubules was less
intense and more luminal than in the proximal tubules.
Unlike any other SIBLING, DMP1 was also clearly ex-
pressed in the thin limb of Henle (Fig. 4B, F, and G)
and in the parietal epithelial cells of Bowman’s capsule
(Fig. 4A and E, arrows). MMP-9 distribution mirrored
that of its SIBLING partner, DMP1, by its expression in
the proximal tubules, distal tubules, thin limb of Henle,
collecting duct, and corresponding parietal epithelial
cells of Bowman’s capsule in serial/near-serial sections
(Fig. 4I to O) (Fig. 4L schematic, red). As with the other
SIBLINGs and MMPs, cells within the glomerular tuft,
all connective tissues, and all blood vessels were nega-
tive for DMP1 and MMP-9. Figure 4H and P represent
sense strand (negative) controls for DMP1 and MMP-9
mRNA, respectively.
DSPP
DSPP staining was intense in the proximal tubules and
less intense but clearly present within the distal tubules at
both the protein (Fig. 3Q to S) and mRNA levels (Fig. 3U
to W). Focal staining was also observed in the collecting
duct (Fig. 3D) at the immunohistochemistry level but like
that for BSP/MMP-2, local expression could not be veri-
fied at the mRNA level by in situ hybridization (Fig. 3W).
Figure 3T (red) is a schematic summary of DSPP distribu-
tion, while Figure 3X represents sense strand (negative)
control for DSPP mRNA.
MEPE
Figure 4T schematic (red) summarizes the distribu-
tion of the fifth SIBLING, MEPE, and indicates the
immunolocalization of MEPE strictly to the proximal
tubules (Fig. 4Q and R) with significantly more inten-
sity in the proximal convoluted tubules than the proxi-
mal straight tubules. This distribution was also verified by
the demonstration of its mRNA to the proximal tubules
by in situ hybridization, although the difference in in-
tensity observed by immunohistochemistry was not re-
flected at the mRNA level (Fig. 4U). The glomeruli, thin
limb of Henle, distal tubules, and collecting duct were
all negative for MEPE at both protein and mRNA levels
(Fig. 4Q to V). Interestingly, MEPE distribution tended
to be on the luminal surface and/or in the luminal half of
the proximal tubule cells (Fig. 4X).
DISCUSSION
To our knowledge this is the first report of the localiza-
tion of all five SIBLINGs in the tubular epithelial cells
of the normal nephron by immunohistochemistry and
in situ hybridization. MMP expression in the kidney has
been widely noted, although reports of their expression in
duct epithelial cells of normal kidney have been less than







Fig. 2. Osteopontin (OPN) and matrix met-
alloproteinase (MMP)-3 localization in mon-
key and rat kidneys. Immunolocalization
(reddish/brown) of OPN (A to C) to the dis-
tal tubules of monkey kidney with prominent
basal localization (A, arrow). Distal convo-
luted tubules in the cortical labyrinth (A) and
distal straight tubules in the medullary rays
(B and C) are positive for osteopontin mon-
oclonal antibody LF-Mb14, and negative for
all other segments, including the glomeruli;
schematic (D) summarizes OPN segmental lo-
calization (red). Positive control (E, arrow)
showing distal tubule localization of Tamm-
Horsefall protein (THP) but without basal
polarity [contrast with (A)]. Antibody re-
sults for OPN were verified by in situ hy-
bridization (F and G) (purple/blue) on corre-
sponding serial sections. Immunolocalization
of rat OPN to the distal tubules (I to K) in
the cortical labyrinth (I), medullary rays (J),
and renal pyramid (K), using LF-Mb14 an-
tibody; representative preimmune IgG neg-
ative control (L), and in situ hybridization
sense strand (H) (negative control) are also
shown. Immunolocalization of MMP-3 to the
distal tubules and proximal tubules (M to O)
in the cortical labyrinth (M), medullary ray
(N), and medullary pyramid (O). In situ hy-
bridization (Q to S) verifying the presence
of MMP-3 mRNA. Schematic summary (P)
(red) of MMP-3 localization and in situ hy-
bridization with sense strand (T) (negative
control) is shown.
direct and clear. Piedagnel et al [39] did report the local-
ization of MMP-2 and MMP-9 in the collecting ducts in
normal rabbit kidney using sheep polyclonal antisera
made against the corresponding human proteins. Other
reports were results involving in vitro studies carried out
on cells thought to represent distinct segments of the
nephron [33, 40–43, 45]. Additional studies have been
reported on the expression of the MMPs during nephro-
genesis, or their profiles in specific kidney pathologies [40,
43, 46–49]. To our knowledge this is also the first report
distinctly delineating the localization of MMP-3 as well
as showing the localization of MMP-2 and MMP-9 in nor-
mal primate adult kidneys by immunohistochemistry and
in situ hybridization.
Following our recent report that the SIBLINGs were
colocalized with their partner MMPs along the entire
length of the ducts of salivary glands [37], we hypothe-
sized that the SIBLINGs may also be present in distantly
related structures such as the kidney. The nephron, be-
ing a more complex structure than the salivary duct sys-
tem, also offered the possibility that the proteins may be
differentially expressed in different functional segments.
Indeed, it has long been known that OPN, a member of
the SIBLING family, is expressed only in kidney distal
tubules in many species [8]. At least three members of
the integrin-binding SIBLING family of secreted pro-
teins bind and activate specific pro-MMPs and can even
prevent TIMPs from inhibiting their corresponding ac-
tive MMPs in vitro [24].
In primate salivary glands, both the SIBLINGS and the
MMPs were always located throughout the ductal system
and were never expressed in the acini [37]. In rodents,
however, all of the SIBLINGs (except DSPP) and their
MMP partners were also expressed in the acini [37]. Fur-
thermore, in the special, androgen-dependent granulated
convoluted tubules of the male mice, none of the SIB-
LINGs or MMPs were expressed [37]. Thus, SIBLINGs
and their cognate MMP are consistently expressed to-
gether in a spatially restricted fashion suggesting that the
SIBLING-MMP pairing may be important in vivo. How-
ever, because all five of the SIBLINGs and the three
MMPs partners are coexpressed in the same cells, hy-
potheses of what the individual parings of SIBLNGs and
MMP may be doing (for example, what are the local sub-
strates of the activated MMP) are difficult to postulate.
We reasoned, therefore, that kidney is an ideal tissue to




















Fig. 3. Localization of bone sialoprotein (BSP), matrix metallopro-
teinase (MMP)-2, and dentin sialophosphoprotein (DSPP). Immunolo-
calization of BSP (reddish/brown) to proximal tubule and distal tubule
(A to C). Distal convoluted tubule and proximal convoluted tubule in
the cortical labyrinth (A), distal straight tubule and proximal straight
tubule in the medullary rays (B and C) are positive for BSP mono-
clonal antibody LF-Mb25; collecting duct (C, ∗) is focally positive for
BSP also seen with polyclonal (LF-84) antibody (data not shown). In
situ hybridization (purple/blue) on corresponding serial sections (E to
G) also showed the presence of BSP mRNA. Collecting duct (G, ∗) is
negative for BSP mRNA. BSP sense strand control was negative (H) for
BSP mRNA. MMP-2 immunolocalization (I to K) in the cortex (I and
J) and medulla (K) showing positive staining of the proximal tubule and
distal tubule was essentially similar to, and verified on corresponding
serial sections by in situ hybridization (M to O). MMP-2 sense strand
(P) was negative for MMP mRNA. The schematics (D and L) sum-
marize BSP and MMP-2 localization, respectively (intense uniform red
indicates “strong” expression; hatched red indicates “some” expression;
and dotted red indicates “focal/low” level expression as explained in Ta-
ble 2 legends). Like BSP, DSPP immunolocalized to the proximal tubule
and distal tubule (Q and R), and to the collecting duct (S) without in
situ hybridization verification of DSPP mRNA in the collecting duct (V
and W, arrows). DSPP mRNA in the proximal tubule and distal tubule
was verifiable by in situ hybridization (U and V). Immunolocalization
of DSPP is summarized in the schematic (T) (intense uniform red in-
dicates “strong” expression; hatched red indicates “some” expression,
and dotted red indicates “focal/low” expression as explained in Table
2 legends). Sense strand in situ hybridization for DSPP mRNA is also
shown (X).
investigate the possibility that the SIBLINGs and their
MMP partners may be differentially expressed along a
ductal system more complex than that found in the sali-
vary gland.
Although our observations for adult human and mon-
key kidneys were virtually the same for the SIBLINGs
Fig. 4. Localization of dentin matrix protein-1 (DMP1), matrix
metalloproteinase-9 (MMP-9), and matrix extracellular phosphoglyco-
protein (MEPE). DMP1 and MMP-9 showed similar immunolocaliza-
tion (A to C and I to K) as summarized in their respective schemat-
ics (D and L) as well as corresponding mRNA distribution (E to G
and M to O). DMP1 immunolocalized to the proximal tubule and dis-
tal tubule (A to C), parietal cells of Bowman’s capsule (A), and the
thin limb of Henle (B). The distal tubuless show reduced expression
of DMP1 as summarized in the schematic (D) (intense uniform red in-
dicates “strong expression; ” hatched red indicates “some” expression
as explained in Table 2 legends). The distribution of DMP1 mRNA to
the proximal tubule and distal tubule (E and F), the parietal cells of
Bowman’s capsule (E), and to the thin limb of Henle (F and G) mirrors
that of MMP-9 (M to O). The sense strands for DMP1 (H) and MMP-
9 (P) in situ hybridization for their respective mRNA was negative.
Immunolocalization of MEPE was limited to the proximal tubule (Q)
with more intensity in the proximal convoluted tubule as summarized in
the schematic (T) (intense uniform red indicates “strong” expression;
hatched red indicates “some” expression as explained in Table 2 leg-
ends). Luminal localization (X, ∗) is also shown. Other segments of the
medullary nephron (R) were essentially negative. MEPE mRNA distri-
bution corresponded to its protein localization in the proximal tubule
(U) with absence in the other segments (V). Representative preimmune
IgG antibody negative control (S) and sense strand in situ hybridization
for MEPE mRNA negative control are also shown. Black arrows show
Bowman’s capsule parietal cell staining, while white arrows show thin
loop of Henle staining.
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and their partner MMPs, results of the monkey sections
are shown here because the small size of the M. fasci-
cularis kidney permitted all three morphologic regions
(cortex medulla and renal calyx) to be probed on a sin-
gle section. Except for DMP1 and MMP-9, which also
showed staining of parietal cells of the Bowman’s cap-
sule, SIBLING and MMP localization were confined to
the tubular epithelial cells of the nephron. The other
glomerular cells, including tuft cells, connective tissue,
blood vessels, and the rest of the kidney parenchyma,
were always devoid of protein and mRNA of the
SIBLINGs and their MMP partners.
Our observation of the localization of OPN is consis-
tent with earlier reports [45, 50, 51] to the extent that OPN
is localized to the distal tubules. However, using several
different antibodies and four species (monkey and rat
data presented, human and mouse data not shown) OPN
was consistently localized to the basal rather than the lu-
minal (apical) region of the distal tubule suggested by
other authors [20]. Salivary gland striated ducts similarly
had a clear basal staining with antibodies to OPN [37].
MMP-3, although found in the same distal tubule cells, did
not have a particularly basal distribution pattern. Brown
et al [50] reported that OPN might be present in the hu-
man collecting duct, but we did not observe any evidence
of OPN expression in the epithelial cells of the adult kid-
ney collecting duct either at the protein or mRNA level
in any of the species studied. Because OPN is known to
be in the urine of many species [52], occasionally one may
expect to find luminal material that may sustain a positive
immunostaining reaction.
Following pathologic stimuli, reports of the expression
of OPN in the proximal tubules in addition to the normal
expression in the distal tubules [11–13, 15, 20] has been
reported. Although the report of Xie et al [20] had indi-
cated that OPN was present in the descending portion of
the thin limb of Henle, and not in the distal tubule of nor-
mal rat kidney, there was neither immnunohistochemistry
nor in situ hybridization results included to substantiate
this observation. We were unable to verify the presence
of OPN in the rat thin limb of Henle and clearly found
it in the location seen for all other reported species, the
distal tubules.
As indicated in the results, mRNAs to BSP and its pro-
tease partner MMP-2 were not detectable in the collect-
ing duct by in situ hybridization in serial sections even
though their respective proteins were demonstrable by
immunohistochemistry. As suggested by Tanney et al [38]
for MMP-2 observed in the collecting duct at protein but
not mRNA levels during nephrogenesis, it can be hypoth-
esized that at least some of the BSP made in the proxi-
mal tubule or distal tubule was secreted into the urine
and became bound to the luminal surfaces of some col-
lecting duct cells. Piedagnel et al [39] detected the pres-
ence of MMP-2 only in the collecting duct segment of the
nephron and therefore suggested that MMP-2 is a spe-
cific marker for the collecting duct segment. With suf-
ficiently sensitive reagents, however, MMP-2 was also
localized to the proximal tubule and distal tubule sug-
gesting that MMP-2 is an unlikely specific marker for
normal collecting ducts. The portions of the kidney that
are positive for the BSP/MMP-2 pair, proximal tubule +
distal tubule (and perhaps collecting duct), are the ones
generally thought to be involved in active ion transport.
Thus they are similar to the salivary gland duct system
in both shared physiologic function and expression of
BSP/MMP-2. The portions of the nephron that are neg-
ative for BSP/MMP-2, the glomerulus and thin limb of
Henle region, are not generally considered to be involved
in high, active transport and may share little or no physio-
logic functions with elements of the salivary gland ductal
system.
DMP1, and its MMP-9 partner, localized to all segment
types and notably, also in the parietal cells of the Bow-
man’s capsule. With respect to MMP-9, this result con-
trasted with those of Piedagnel et al [39] who reported
the expression of MMP-9 in only the collecting duct seg-
ment of normal rat kidney as well as those of Knowlden
et al [53] who reported localization in normal glomerular
mesangial cells based on human cell culture studies.
The two SIBLINGs, DSPP and MEPE (with yet to be
identified MMP partners), also localized to specific seg-
ments of the nephron. The apparently stronger intensity
of DSPP staining in the proximal tubule luminal surface
than in the distal tubule suggests that DSPP is secreted
into the lumen of the nephron, and possibly binds to
specific luminal surfaces of this nephron segment. Sim-
ilarly, the apparent difference in intensity of MEPE in
the proximal convoluted tubule and proximal straight
tubule observed by immunohistochemistry may be due to
the presence of a surface binding protein for MEPE on
the luminal surface of the proximal convoluted tubule.
While MMPs were traditionally thought to be lim-
ited to areas of development, wound repair, cellular
migration, or matrix turnover, they now are increas-
ingly thought to be involved in the homeostasis of
normal tissue elements. It has been suggested that the
segmental preferences for expression of the MMPs in
the nephron reflect distinct transcriptional control mech-
anisms arising from major differences in the structures of
the 5′ regulatory regions of these genes [54]. Given the
SIBLING/MMP partnership we postulate, by extension,
that the presence of similar major differences in the struc-
ture of the 5′ regulatory regions of the SIBLING genes
may account for transcriptional control differences caus-
ing each SIBLING to be localized to specific segments
of the nephron. It is predictable that such control mech-
anisms may, in disease conditions, alter the expression
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of a particular SIBLING or MMP at additional segmen-
tal locations to that in normal conditions. For example,
in certain pathologic conditions, OPN is expressed in the
proximal convoluted tubule in addition to its normal ex-
pression in the distal tubule.
Our current results support the hypothesis that all of
the SIBLINGs appear to have a function(s) in addition to
control of mineralization. A final hypothesis of the func-
tion(s) of the SIBLINGs must eventually include the fol-
lowing: (1) retained ability to bind to integrins throughout
evolution; (2) coexpression with MMPs (for at least three
of the five known SIBLINGs); and (3) the distribution of
the proteins within the mineralized and nonmineralized
tissues.
The physiology of the nephron is one of the most highly
studied and best understood complex structures in na-
ture. While work remains to be done, the basic functions
of the different segments of the nephron are well un-
derstood. The epithelial cells produce and maintain cell
surface proteins, basement membranes, and other peri-
cellular matrices that are critical to the different functions
performed by the different segments. While proteins such
as type IV collagen and laminin are always part of the
basement membrane, other gene products probably dif-
fer among the segments so that the local microenviron-
ments best fit the different physiologic functions being
performed. For example, due to the filtering properties
of the glomerular basement membrane, it is clearly dif-
ferent in content than that found in the proximal tubule
or the loop of Henle. Furthermore, the assembly, main-
tenance, and local turnover of these different basement
membranes, pericellular matrices, and cells surface pro-
teins are probably the responsibility of each epithelial
cell. Proteases would certainly be required for these pro-
cesses and this paper shows that each segment of the
nephron expresses one or more the three MMPs investi-
gated. Activation of these MMPs historically has required
the removal of their inhibitory propeptides, but it has re-
cently been shown that three members of the SIBLING
family of proteins can bind and activate their partner
MMPs without removal of the propeptides in vitro. The
fact that we were able to show that every time a nephron
cell produces a specific SIBLING protein, it also invari-
ably is making its partner MMP clearly suggested that
the active SIBLING-MMP complex will be formed lo-
cally. The differential expression of the three SIBLING-
MMP complexes suggests that there are likely differ-
ent target proteins that each cell is modifying. MMP-9
is known to turnover type IV collagen so the coexpres-
sion of DMP-1 and MMP-9 along the entire length of
the nephron suggests that this complex may be involved
in the turnover of this ubiquitous basement membrane
component. The more restricted pattern of BSP/MMP-
2 and OPN/MMP3 partners may reflect the turnover of
a different basement membrane or pericellular proteins
that are also restricted to those segments of the nephron.
The question of whether these complexes are involved in
the routine turnover of normal, undamaged pericellular
proteins or are used to specifically remove proteins dam-
aged by the oxidative byproducts invariably generated by
these highly metabolically active cells must be answered
in future studies.
In recent years it has also become widely accepted that
MMPs are often involved in the processing of a vari-
ety of cell surface proteins. We find this particularly ex-
citing because BSP has recently been shown to bridge
MMP-2 to avb 3 integrin, thereby making it an excel-
lent candidate for modifying cell surface proteins [55].
OPN bridges MMP-3 to cell surfaces and DMP1 does the
same for MMP-9 [manuscript in preparation]. The differ-
ent segments of the nephron each have many different
cell surface proteins such as water channels; ion pumps
and channels; protein, peptide and amino acid trans-
porters; assorted carbohydrate transporters and lectins;
and numerous receptors involved in signal transduction
to name a few. Some of these cell surface proteins re-
quire proteolytic events to be activated while others are
inactivated prior to recycling by the cell. Proteases may
also degrade proteins bound to various receptors allow-
ing the disengagement of the receptor from the bound
protein. The SIBLING/MMP/cell surface receptor com-
plexes, because they may already be localized to the spe-
cific cell surfaces, offer unique opportunities for cells to
specifically modify various cell surface proteins under
highly controlled spatial conditions. The expression of
MMP-3 in both the proximal and distal tubules while its
SIBLING partner, OPN, is expressed only in the distal
tubule offers insight into the different roles that MMP-
3 may play in the normal kidney. The soluble form of
MMP-3 may be involved in the turnover of local matrix
components of the proximal tubule while in the distal
tubule, where OPN is expressed, it may also be held on
the cell surface where it can modify specific cell surface
proteins.
The kidney offers a unique opportunity in future stud-
ies to identify the specific protein substrates for each
SIBLING-MMP partnership and will also serve to ver-
ify the identity of the MMP partners for MEPE and
DSPP as they are proposed. Furthermore, the future
documentation of the up- or down-regulation of these
sometimes destructive gene products in various kidney
diseases may offer new opportunities for intervention
and prevention. For example, in diseases in which both
the MMP and its SIBLING partner are up-regulated,
any synthetic MMP protease inhibitor that may be pro-
posed to be used to treat the disorder should first be
shown to work in the presence of that MMP’s SIBLING
partner.
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